Stephan Petersenn

List of Publications by Year
in descending order

42	2,935	279798	243625
papers	citations	23 h-index	44 g-index

44	44	44	2249
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Pituitary Society Delphi Survey: An international perspective on endocrine management of patients undergoing transsphenoidal surgery for pituitary adenomas. Pituitary, 2022, 25, 64-73.	2.9	7
2	Overnight 1Âmg dexamethasone suppression test and 24Âh urine free cortisolâ€"accuracy and pitfalls when screening for Cushingâ€™s syndrome. Pituitary, 2022, 25, 693-697.	2.9	2
3	Biochemical diagnosis of Cushingâ€™s disease: Screening and confirmatory testing. Best Practice and Research in Clinical Endocrinology and Metabolism, 2021, 35, 101519.	4.7	14
4	Consensus on diagnosis and management of Cushing's disease: a guideline update. Lancet Diabetes and Endocrinology,the, 2021, 9, 847-875.	11.4	315
5	Predictive factors for responses to primary medical treatment with lanreotide autogel 120Âmg in acromegaly: post hoc analyses from the PRIMARYS study. Pituitary, 2020, 23, 171-181.	2.9	22
6	Biochemical diagnosis in prolactinomas: some caveats. Pituitary, 2020, 23, 9-15.	2.9	14
7	Diagnosis and management of prolactinomas: current challenges. Pituitary, 2020, 23, 1-2.	2.9	13
8	Multidisciplinary management of acromegaly: A consensus. Reviews in Endocrine and Metabolic Disorders, 2020, 21, 667-678.	5.7	183
9	Use of late-night salivary cortisol to monitor response to medical treatment in Cushingâ€™s disease. European Journal of Endocrinology, 2020, 182, 207-217.	3.7	29
10	Longâ€term efficacy and safety of onceâ€monthly pasireotide in Cushing's disease: A Phase III extension study. Clinical Endocrinology, 2019, 91, 776-785.	2.4	24
11	Pituitary Disease in Pregnancy: Special Aspects of Diagnosis and Treatment?. Geburtshilfe Und Frauenheilkunde, 2019, 79, 365-374.	1.8	16
12	MRI T2 signal intensity and tumor response in patients with GH-secreting pituitary macroadenoma: PRIMARYS post hoc analysis. European Journal of Endocrinology, 2019, 180, 155-164.	3.7	19
13	European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas. European Journal of Endocrinology, 2018, 178, G1-G24.	3.7	387
14	Pituitary disease management during pregnancy: an overview. Minerva Endocrinology, 2018, 43, 420-422.	1.1	1
15	Secondary adrenal insufficiency in pregnancy: any differences?. Minerva Endocrinology, 2018, 43, 446-450.	1.1	1
16	Neuroendocrine neoplasms â€“ still a challenge despite major advances in clinical care with the development of specialized guidelines. Reviews in Endocrine and Metabolic Disorders, 2017, 18, 373-378.	5.7	6
17	How to manage pasireotide, when using as medical treatment for Cushingâ€™s disease. Endocrine, 2015, 50, 526-528.	2.3	5
18	Pituitary-directed medical therapy in Cushingâ€™s disease. Pituitary, 2015, 18, 238-244.	2.9	8

#	Article	IF	Citations
19	Medical therapy for Cushingâ€™s disease: adrenal steroidogenesis inhibitors and glucocorticoid receptor blockers. Pituitary, 2015, 18, 245-252.	2.9	21
20	THERAPY OF ENDOCRINE DISEASE: Outcomes in patients with Cushing's disease undergoing transsphenoidal surgery: systematic review assessing criteria used to define remission and recurrence. European Journal of Endocrinology, 2015, 172, R227-R239.	3.7	114
21	Computed tomography criteria for discrimination of adrenal adenomas and adrenocortical carcinomas: analysis of the German ACC registry. European Journal of Endocrinology, 2015, 172, 415-422.	3.7	43
22	Cushing disease: Where do we stand, where are we heading?. Pituitary, 2015, 18, 179-180.	2.9	1
23	Treatment of malignant phaeochromocytoma with a combination of cyclophosphamide, vincristine and dacarbazine: own experience and overview of the contemporary literature. Clinical Endocrinology, 2015, 82, 84-90.	2.4	21
24	Pharmacokinetics, pharmacodynamics, and safety of pasireotide LAR in patients with acromegaly: A randomized, multicenter, openâ€label, phase I study. Journal of Clinical Pharmacology, 2014, 54, 1308-1317.	2.0	28
25	Long-term efficacy and safety of subcutaneous pasireotide in acromegaly: results from an open-ended, multicenter, Phase II extension study. Pituitary, 2014, 17, 132-140.	2.9	43
26	Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushing's disease: results from a Phase <scp>III</scp> study. Clinical Endocrinology, 2014, 81, 408-417.	2.4	95
27	Tumor Shrinkage With Lanreotide Autogel 120 mg as Primary Therapy in Acromegaly: Results of a Prospective Multicenter Clinical Trial. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 1282-1290.	3.6	146
28	New avenues in the medical treatment of Cushingâ€™s disease: corticotroph tumor targeted therapy. Journal of Neuro-Oncology, 2013, 114, 1-11.	2.9	28
29	Pasireotide (SOM230), a Novel Multireceptorâ€Targeted Somatostatin Analogue, Is Well Tolerated When Administered as a Continuous 7â€Day Subcutaneous Infusion in Healthy Male Volunteers. Journal of Clinical Pharmacology, 2012, 52, 1017-1027.	2.0	27
30	Salivary cortisol as a diagnostic tool for Cushing's syndrome and adrenal insufficiency: improved screening by an automatic immunoassay. European Journal of Endocrinology, 2012, 166, 613-618.	3.7	71
31	Medical management of Cushingâ€™s disease: what is the future?. Pituitary, 2012, 15, 330-341.	2.9	82
32	A 12-Month Phase 3 Study of Pasireotide in Cushing's Disease. New England Journal of Medicine, 2012, 366, 914-924.	27.0	550
33	Tolerability and Dose Proportional Pharmacokinetics of Pasireotide Administered as a Single Dose or Two Divided Doses in Healthy Male Volunteers: A Single-Center, Open-Label, Ascending-Dose Study. Clinical Therapeutics, 2012, 34, 677-688.	2.5	15
34	Prolactinomas, Cushing's disease and acromegaly: debating the role of medical therapy for secretory pituitary adenomas. BMC Endocrine Disorders, 2010, 10, 10.	2.2	48
35	The Rational Use of Pituitary Stimulation Tests. Deutsches Ärzteblatt International, 2010, 107, 437-43.	0.9	29
36	Diagnosis of secondary adrenal insufficiency in patients with hypothalamicâ€“pituitary disease: comparison between serum and salivary cortisol during the high-dose short synacthen test. European Journal of Endocrinology, 2009, 160, 9-16.	3.7	51

#	Article	IF	Citations
37	Late-night and low-dose dexamethasone-suppressed cortisol in saliva and serum for the diagnosis of cortisol-secreting adrenal adenomas. European Journal of Endocrinology, 2009, 161, 747-753.	3.7	25
38	Clinical Predictors and Algorithm for the Genetic Diagnosis of Pheochromocytoma Patients. Clinical Cancer Research, 2009, 15, 6378-6385.	7.0	160
39	3 Rationale for treatment and therapeutic options in Cushing's disease. Best Practice and Research in Clinical Endocrinology and Metabolism, 2009, 23, S15-S22.	4.7	24
40	A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LARï¿½(long-acting repeatable octreotide) in the primary therapy of patients with acromegaly. Clinical Endocrinology, 2007, 66, 859-868.	2.4	202
41	Diagnostic Value of Biochemical Parameters in the Differential Diagnosis of an Adrenal Mass. Annals of the New York Academy of Sciences, 2006, 1073, 348-357.	3.8	9
42	Genomic structure and transcriptional regulation of the human somatostatin receptor type 2. Molecular and Cellular Endocrinology, 1999, 157, 75-85.	3.2	33